HomeCompareRMGNF vs ABBV

RMGNF vs ABBV: Dividend Comparison 2026

RMGNF yields 5.01% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RMGNF wins by $61.60M in total portfolio value
10 years
RMGNF
RMGNF
● Live price
5.01%
Share price
$42.01
Annual div
$2.11
5Y div CAGR
76.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$61.71M
Annual income
$54,426,961.87
Full RMGNF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RMGNF vs ABBV

📍 RMGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRMGNFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RMGNF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RMGNF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RMGNF
Annual income on $10K today (after 15% tax)
$426.08/yr
After 10yr DRIP, annual income (after tax)
$46,262,917.59/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RMGNF beats the other by $46,241,861.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RMGNF + ABBV for your $10,000?

RMGNF: 50%ABBV: 50%
100% ABBV50/50100% RMGNF
Portfolio after 10yr
$30.90M
Annual income
$27,225,866.81/yr
Blended yield
88.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RMGNF
No analyst data
Altman Z
2.8
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RMGNF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRMGNFABBV
Forward yield5.01%3.06%
Annual dividend / share$2.11$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR76.5%40.6%
Portfolio after 10y$61.71M$102.3K
Annual income after 10y$54,426,961.87$24,771.77
Total dividends collected$61.10M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RMGNF vs ABBV ($10,000, DRIP)

YearRMGNF PortfolioRMGNF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,585$884.75$11,550$430.00+$35.00RMGNF
2$14,086$1,690.70$13,472$627.96+$614.00RMGNF
3$18,464$3,391.10$15,906$926.08+$2.6KRMGNF
4$27,088$7,331.91$19,071$1,382.55+$8.0KRMGNF
5$46,728$17,743.46$23,302$2,095.81+$23.4KRMGNF
6$100,487$50,488.99$29,150$3,237.93+$71.3KRMGNF
7$286,622$179,100.49$37,536$5,121.41+$249.1KRMGNF
8$1,149,352$842,666.24$50,079$8,338.38+$1.10MRMGNF
9$6,803,716$5,573,909.93$69,753$14,065.80+$6.73MRMGNF
10$61,706,938$54,426,961.87$102,337$24,771.77+$61.60MRMGNF

RMGNF vs ABBV: Complete Analysis 2026

RMGNFStock

RHI Magnesita N.V., together with its subsidiaries, develops, produces, sells, installs, and maintains refractory products and systems used in industrial high-temperature processes worldwide. It offers magnesia spinel, dolomite, dolomite-magnesia, magnesia-chrome, alumina, alumina silicate, and mortars for the cement industry; shaped products based on silicon carbide, magnesia, zirconium, fireclay, and alumina; unshaped refractories; and high-temperature insulation, and ceramic and metallic anchoring systems. The company also provides induction and electric arc furnaces, AOD converters, dome and delta, ladles, isostatically pressed products, and slide gates. In addition, the company offers zircon-magnesia, mullite /andalusite, chrome-alumina, zircon, silica, and calcium aluminate materials. Further, the company provides high-purity magnesia and magnesia-chromite bricks, magnesia-carbon bricks, concrete with anti-wetting system, ceramic and metal anchors, sense and insulating concretes, ramming mixes, and low cement castables, as well as precast shapes, alumina-silica, insulating monolithic parts; and monolithic products. Additionally, it provides raw, caustic, and sintered magnesia, dolomite and sintered dolomite, slag conditioners, magnesium oxide, spinels, agalmatolite, chromite, grogs, and commodities. The company also offers electromechanical maintenance, repairs, assemblies, refractory maintenance and application; solutions development and monitoring; engineering, projects, lining, and metal working factory services. In addition, it provides iron, steel, continuous casting, and non-ferrous solutions. RHI Magnesita N.V. offers solutions for various ladles, tundish, hydraulical or electrical power, steel plant aggregates, and robotic handling sectors. The company was founded in 1834 and is headquartered in Vienna, Austria.

Full RMGNF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RMGNF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RMGNF vs SCHDRMGNF vs JEPIRMGNF vs ORMGNF vs KORMGNF vs MAINRMGNF vs JNJRMGNF vs MRKRMGNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.